Cargando…

Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials

Detalles Bibliográficos
Autores principales:	Ledenko, Matthew, Antwi, Samuel O., Arima, Shiho, Driscoll, Julia, Furuse, Junji, Klümpen, Heinz-Josef, Larsen, Finn Ole, Lau, David K., Maderer, Annett, Markussen, Alice, Moehler, Markus, Nooijen, Lynn E., Shaib, Walid L., Tebbutt, Niall C., André, Thierry, Ueno, Makoto, Woodford, Rachel, Yoo, Changhoon, Zalupski, Mark M., Patel, Tushar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404243/ https://www.ncbi.nlm.nih.gov/pubmed/36033540 http://dx.doi.org/10.3389/fonc.2022.963753

Ejemplares similares

The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
por: Michel, Maurice, et al.
Publicado: (2021)

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases
por: Desuki, Alexander, et al.
Publicado: (2019)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients
por: Haupts, Anna, et al.
Publicado: (2021)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Thomaidis, Thomas, et al.
Publicado: (2014)

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy
por: Wehler, Thomas C., et al.
Publicado: (2012)

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
por: Moehler, Markus, et al.
Publicado: (2019)

Young-onset gastric cancer and Epstein–Barr Virus (EBV) – a major player in the pathogenesis?
por: Moore, Assaf, et al.
Publicado: (2020)

Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
por: Casadio, M., et al.
Publicado: (2022)

Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2018)

A deep learning approach for detecting liver cirrhosis from volatolomic analysis of exhaled breath
por: Wieczorek, Mikolaj, et al.
Publicado: (2022)

Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
por: Franssen, Stijn, et al.
Publicado: (2023)

Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry
por: Nooijen, Lynn E., et al.
Publicado: (2022)

Gallbladder cancer mimicking perihilar cholangiocarcinoma—considerable rate of postoperative reclassification with implications for prognosis
por: Nooijen, Lynn E., et al.
Publicado: (2023)

Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck
por: Shaib, Walid, et al.
Publicado: (2012)

TTF-1 Expression in Rectal Adenocarcinoma: A Case Report and Review of the Literature
por: Belalcazar, Astrid, et al.
Publicado: (2016)

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
por: Sprinzl, Martin F, et al.
Publicado: (2006)

Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial
por: Thomaidis, Thomas, et al.
Publicado: (2014)

Nationwide treatment and outcomes of perihilar cholangiocarcinoma
por: van Keulen, Anne‐Marleen, et al.
Publicado: (2021)

Amelioration of Symptoms and Reduction of VIP Levels after Hepatic Artery Chemoembolization in a Patient with Sandostatin Resistant VIPoma
por: Shaib, Walid, et al.
Publicado: (2010)

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018)

Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)
por: Rades, Dirk, et al.
Publicado: (2020)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?
por: Furuse, Junji
Publicado: (2019)

Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan
por: Furuse, Junji
Publicado: (2019)

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
por: Gairing, Simon Johannes, et al.
Publicado: (2021)

Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience
por: Rassam, F., et al.
Publicado: (2018)

Unusual Position and Presentation of Frontobasal Meningoencephalocela
por: Busic, Zeljko, et al.
Publicado: (2015)

CD44 variant‐dependent redox status regulation in liver fluke‐associated cholangiocarcinoma: A target for cholangiocarcinoma treatment
por: Thanee, Malinee, et al.
Publicado: (2016)

Lost in translation: confusion on resection and dissection planes hampers the interpretation of pathology reports for perihilar cholangiocarcinoma
por: Roos, Eva, et al.
Publicado: (2019)

Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma
por: Braconi, Chiara, et al.
Publicado: (2010)

Case Report: Simultaneously Developed Amyopathic Dermatomyositis and Autoimmune Sclerosing Cholangitis – a Coincidence or a Shared Immunopathogenesis?
por: Ledenko, Tomislav, et al.
Publicado: (2022)

The Influence of Hepatic Steatosis and Fibrosis on Postoperative Outcomes After Major Liver Resection of Perihilar Cholangiocarcinoma
por: van Keulen, Anne-Marleen, et al.
Publicado: (2023)

Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial
por: Furuse, Junji, et al.
Publicado: (2022)

Targeted Therapy for Biliary Tract Cancer
por: Furuse, Junji, et al.
Publicado: (2011)

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
por: Okusaka, Takuji, et al.
Publicado: (2020)

Treatments for elderly cancer patients and reforms to social security systems in Japan
por: Nagashima, Fumio, et al.
Publicado: (2022)

Recurrent cholangiocarcinoma with long-term survival by multimodal treatment: A case report
por: Sota, Yuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3fkptd9fo9g0ppa4p8msed11ul